Latest News

  • Alkermes Highlights Ongoing Commitment to Research and Innovation in Depression and Schizophrenia at 2018 Psych Congress Read More
  • Alkermes to Host Conference Call to Discuss Third Quarter 2018 Financial Results Read More
  • Alkermes Initiates Clinical Evaluation of Novel Immuno-Oncology Drug Candidate ALKS 4230 in Combination With PD-1 Inhibitor Pembrolizumab Read More

Investors

Working at Alkermes